SCHEMBL4501469

SCHEMBL4501469

COc1ccc2cc(C(=O)O)c(NCc3cccc(Cl)c3)nc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APEX1 P27695 2/20 0.49
SMN1; SMN2 Q16637 3/20 0.47
MAPK1 P28482 2/20 0.47
LMNA P02545 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
HPGD P15428 1/20 0.47
GFER P55789 1/20 0.47
AKR1C3 P42330 1/20 0.46
AKR1C2 P52895 1/20 0.46
CSNK1D P48730 1/20 0.46
RAF1 P04049 1/20 0.45
HTT P42858 1/20 0.45
HPGDS O60760 1/20 0.44
APP P05067 2/20 0.43
EGFR P00533 1/20 0.43
MAOB P27338 1/20 0.43
GSR P00390 1/20 0.43
HCRTR1 O43613 1/20 0.43
PDE5A O76074 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4500058 0.91 SMN1; SMN2 (0.53) APEX1SMN1; SMN2MAPK1LMNAMEN1
SCHEMBL4492756 0.90 MEN1 (0.48) APEX1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL4489260 0.89 HPGDS (0.55) SMN1; SMN2MAPK1LMNAHPGDHPGDS
SCHEMBL4490500 0.88 CTNNB1 (0.51) LMNAMEN1KMT2AAKR1C3AKR1C2
SCHEMBL4496183 0.88 LMNA (0.46) APEX1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL4484547 0.88 APP (0.48) APEX1SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL4487073 0.86 KDM4E (0.53) MEN1KMT2AHPGDAKR1C3AKR1C2
SCHEMBL4493680 0.85 MITF (0.56) MEN1KMT2AAKR1C3AKR1C2APP
SCHEMBL4482214 0.84 AURKA (0.49) SMN1; SMN2APP
SCHEMBL4489700 0.84 HIF1A (0.58) SMN1; SMN2LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482455-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-01-27 US claimed
EP-1556379-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-13 EP claimed
US-20060106058-A1 Chemical compounds BURGESS JOELLE L 2006-05-18 US claimed
EP-1556379-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-07-27 EP claimed
WO-2004034985-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO claimed
US-7482455-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-01-27 US disclosed
EP-1556379-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-13 EP disclosed
US-20060106058-A1 Chemical compounds BURGESS JOELLE L 2006-05-18 US disclosed
EP-1556379-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-07-27 EP disclosed
WO-2004034985-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106058-A1 Chemical compounds YARS1, DAPK3, NEK3 APEX1 822/4885SMN1; SMN2 4328/4885MAPK1 2323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.